CORMEDIX INC. Available-for-sale Securities, Amortized Cost Basis
CORMEDIX INC. (CRMD) had Available-for-sale Securities, Amortized Cost Basis of $22.62 million as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2021-05-13
- 2021-03-31: Available-for-sale Securities, Amortized Cost Basis $22.62M.
- 2020-12-31: Available-for-sale Securities, Amortized Cost Basis $7.63M.
- 2020-09-30: Available-for-sale Securities, Amortized Cost Basis $7.64M.
- 2020-06-30: Available-for-sale Securities, Amortized Cost Basis $7.62M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2021-03-31 | $22.62M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $7.63M 10-Q · filed 2021-05-13 |
| 2020-09-30 | $7.64M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $7.62M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $12.56M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $15.46M 10-K · filed 2021-03-30 |
| 2019-09-30 | $15.38M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $15.30M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $15.21M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $1.18M 10-K · filed 2020-03-16 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-14 |
| 2018-03-31 | $3.66M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $7.64M 10-K · filed 2019-05-29 |
| 2017-09-30 | $9.40M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $17.27M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $7.24M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $12.21M 10-K · filed 2018-03-19 |
| 2016-09-30 | $20.14M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $20.11M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $20.09M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $26.95M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |